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expenditures in the ≤ 62 cohort. CONCLUSIONS: HE is a growing problem in the US 
and becoming increasingly costly condition for the Medicare population.
Gastrointestinal DisorDers - Patient-reported outcomes & Patient  
Preference studies
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OBJECTIVES: Estimating health-related utility weights in Crohn’s Disease (CD) 
patients is crucial for assessing the cost-effectiveness of new pharmaceutical 
interventions. However, values used in these analyses are usually based on sec-
ondary data and vary substantially among studies. We estimated utility weights 
in a consecutive sample of real-world CD patients. METHODS: Patients enrolled 
in an ongoing socio-economic study of CD in the Israeli adult patient population 
completed the self-administered SF-36 questionnaire and were assessed for their 
current clinical status, including the Harvey-Bradshaw Index (HBI) of disease sever-
ity. Patients were classified to one of the four disease states: disease remission 
(HBI< 5); mild disease (HBI 5-7); moderate disease (HBI 8-16), and severe disease 
(HBI> 16). For each patient enrolled we calculated a utility weight using the SF-6D 
preference-based scoring system developed by Brazier et al. RESULTS: The cohort 
comprised of 373 patients: (39.4% male), with mean age of 37.8 (±14.2) years, 14.5 
(±2.8) years of education, and 11.8 (±9.0) years elapsed since first diagnosis. The 
average HBI was 6.7 (± 5.6); 148 patients were in remission state, 79 had mild disease, 
121 moderate and 25 severe disease. The SF-6D utility weights were correlated with 
the HBI (-0.341; p< 0.0001). The mean utility weights for each disease state were 
as follows: disease remission: 0.720 (±0.141); mild disease; 0.700 (±0.123); moder-
ate disease: 0.603 (±0.109); severe disease: 0.531 (±0.135); p< 0.001. The significant 
predictors of utility weights in a multivariable regression analysis were the HBI 
(β = -0,440; p< 0.001), years of education (β = 0.104; p= 0.034), and time since diagnosis 
(β = 0.150; p= 0.007); (R2 = 0.246). CONCLUSIONS: CD patients suffer from a deprived 
quality of life even in the remission and mild stages of the disease. Utility weights 
for these patients were generally lower as compared to values used in published 
cost-effectiveness analyses. These values should be considered when assessing the 
value for money of future interventions for CD.
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OBJECTIVES: Eosinophilic Esophagitis (EoE) is an inflammatory disorder that can 
have an impact on quality of life in individuals. The psychometric properties of 
the Dysphagia Symptom Questionnaire (DSQ) were assessed in a Phase 2, ran-
domized, double-blind, placebo controlled study of oral budesonide suspension 
with an open-label extension program. METHODS: The evaluation focused on three 
items of the DSQ. Psychometric data were analyzed against the FDA guidance and 
included item level analysis as well as score validation including floor/ceiling, item 
discrimination, construct validity (concurrent validity and known group’s method), 
test-retest reliability, responsiveness, and calculation of minimally important differ-
ences (MID). RESULTS: Patients were 69% male, 62% age ≥ 18, 95% white. Test-retest 
reliability was strong (r= 0.82). Floor/ceiling levels were below the criteria (≤ 9%) for all 
items (range 6.5-8.6%). There was strong item discrimination with 98.1% of patients 
indicating dysphagia in the quartile of DSQ scores. Physician’s global ratings of 
severity and EoE symptom scores were consistent with monotonically increasing 
DSQ scores. Anchor-based MIDs were 6.5 “a little better” and 13.5 “better” respec-
tively. CONCLUSIONS: The DSQ is a reliable and valid measure able to clinically 
discriminate patients along the continuum of dysphagia severity.
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OBJECTIVES: To study the variations in self-reported health status of mainland 
Chinese patients with chronic hepatitis B (CHB) prior to initiating nucleos(t)ide 
analogues (NUC) treatment. METHODS: This study drew the baseline data of the 
EVOLVE study, an ongoing observational clinical study of NUCs for treating CHB 
patients with or without compensated cirrhosis in China. All patients underwent a 
basket of tests for liver functions and information on their clinical characteristics, 
life styles, health status (using the EQ-5D-3L questionnaire), and socio-economic 
status was obtained from medical records or personal interviews. Variations in self-
reported health problems and global health were analyzed with logistic and linear 
regression models, respectively, to identify significant predictors using a stepwise 
selection method. RESULTS: Two thousand nine hundred and fifty-eight of the 
3,434 NUC naïve CHB patients enrolled from 63 hospitals across China (mean age: 
39.3 years; male: 73.1%; HBeAg positive: 61.1%; compensated cirrhosis: 20.4%) were 
included in this analysis. Among those, less than 2% reported problems in mobility, 
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OBJECTIVES: The approval of direct-acting antivirals for Interferon-free treatment 
revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two 
treatment regimens for genotype 1 infection received approval in the European 
Union: Sofosbuvir and Ribavirin for 24 weeks and Sofosbuvir and Simeprevir with or 
without Ribavirin for 12 weeks. We aim to analyze the cost-effectiveness of both reg-
imens in Germany. METHODS: We set up a Markov model with a lifetime horizon to 
simulate immediate treatment success and long-term disease progression for treat-
ment-naive patients. The model analyzes both shortterm and longterm costs and 
benefits from the perspective of the German Statutory Health Insurance. We apply 
the efficiency frontier method, which was suggested by German Institute for Quality 
and Efficiency in Health Care for cost-effectiveness analysis in Germany. RESULTS: 
The efficiency frontier is defined by dual therapy and first generation direct-acting 
antiviral Boceprevir, yielding a maximum of € 1,447.69 per additional percentage 
point of sustained virologic response gained. Even without rebates, Sofosbuvir/
Simeprevir is very close with € 1,560.13 per additional percentage point. It is both 
more effective and less expensive than Sofosbuvir/Ribavirin. CONCLUSIONS: In 
addition to higher sustained virologic response rates, new direct-acting antivirals 
save long-term costs by preventing complications such as liver cirrhosis, hepa-
tocellular carcinoma and ultimately liver transplants, thereby offsetting part of 
higher drug costs. Our findings are in line with the guidance published by German 
Society for Gastroenterology, Digestive and Metabolic Diseases, which recommends 
Sofosbuvir/Simeprevir for Interferon ineligible or intolerant patients.
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OBJECTIVES: This study reports the long-term cost per sustained virologic response 
(SVR) with Viekira Pak (ombitasvir, paritaprevir and ritonavir, dasabuvir) with and 
without ribavirin and standard of care in the US, including sofosbuvir plus sime-
previr (SOF+SMV) and sofosbuvir plus peg-interferon and ribavirin (SOF+PR), among 
patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. METHODS: 
A Markov cost-effectiveness model was used to estimate the long-term cost of HCV. 
The analysis modeled independent cohorts of GT1 HCV patients over a lifetime 
horizon with annual cycles from a US payer perspective. Liver disease progression 
was assessed based on previous natural history model. Direct medical costs (in 2014 
prices and discounted at 3% per year) were obtained from the published literature. 
Efficacy and safety data were obtained from published clinical trials. SVR rates 
were stratified by patient treatment history, cirrhosis status, and sub-genotype, 
where available. Long-term cost per SVR for a patient segment was calculated by 
dividing total cost of HCV over patient’s lifetime by the mean SVR rate in that 
patient segment. RESULTS: The long-term cost per SVR with Viekira Pak ranged 
from $88,305 to $94,433 in GT1 non-cirrhotic patients (12-week regimen), $125,748 
(12-week) to $216,520 (24-week) in GT1 cirrhotic patients, $94,433 to $141,413 in GT1a 
and $88,332 to $125,748 in GT1b treatment-naïve patients (12-week). Long-term 
cost per SVR with SOF+SMV was $164,725 (12-week) in GT1 non-cirrhotic patients, 
and $341,569 (24-week) in GT1 cirrhotic patients, all treatment histories combined. 
Long-term cost per SVR with SOF+PR was $116,713 in GT1a and $134,561 in GT1b 
naïve patients (12-week). CONCLUSIONS: The long-term cost per SVR was lower in 
non-cirrhotic than in cirrhotic patients across all regimens. The results of this study 
suggest that the use of Viekira Pak is a clinically and economically viable strategy 
for GT1 HCV treatment.
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OBJECTIVES: Hepatic encephalopathy (HE) is a major complication of liver disease 
and is becoming more problematic in an aging population with cirrhosis. Medicare 
is a United States (US) government-sponsored health insurance program that guar-
antees access to healthcare for all individuals 65 or older, or who are younger with 
disability. The objective of this study was to estimate the annual healthcare expen-
ditures of patients with HE from a Medicare perspective. METHODS: Inpatient, 
Outpatient, and Master Beneficiary Research Identifiable Files (RIFs) from the 
Medicare 5% Sample were utilized for this study. Medicare 5% Sample is a nation-
ally representative sample of healthcare claims data for the Medicare population. 
RIFs include procedure codes, diagnosis codes, reimbursement, and demographic 
information. To be eligible patients had to have a primary diagnosis code of HE dur-
ing an inpatient hospitalization. Healthcare utilization/expenditures for inpatient 
(IP) and outpatient (OP) procedures for the calendar year 2012 were estimated overall 
and by age cohorts: ≤ 62, 63-67, 68-72, 73-77, 78-82, 83+. RESULTS: A total of 1,113 
patients were identified with HE in 2012 (47% were male). 27% of the patients were 
≤ 62 years of age while 11% were 83 or older. The most common chronic comorbid 
condition was hypertension (75%) and 41% had renal failure. The mean total number 
of visits per HE patient was 13.4 (Mean number of IP and OP visits = 2.4 and 11.0, 
respectively) and varied across age cohorts 14.6 in the ≤ 62 cohort to 10.7 in the 83+ 
cohort; p< 0.0001. For patients who had an IP visit the mean length of stay was 5.9 
days. Mean inpatient expenditures ranged from $25,364 to $58,625 with the highest 
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OBJECTIVES: Patients with Clostridium difficileinfection (CDI) can experience long-
term symptoms that resemble a chronic disease state. Despite this, a health-related 
quality of life (HRQOL) instrument specific for patients with CDI does not exist. 
The goal of this study was to develop and validate a disease specific instrument to 
assess HRQOL in patients with CDI. METHODS: A systematic literature review was 
conducted to identify HRQOL instruments and questions related to general health 
(n= 3) or gastrointestinal disease (n= 13) related to CDI HRQOL. Removing duplicate 
questions and using direct patient (n= 10) or clinician (n= 10) interviews, a 36-item 
survey specific to CDI HRQOL was developed. Test-retest and acceptability of item 
selection was tested on 20 CDI patients and 20 healthy volunteers. The Cdiff36 
HRQOL survey was then tested using 100 patients with CDI and compared to the 
RAND Short-Form 36 (SF-36) Health Survey. Domains containing questions with a 
correlation coefficient of > 0.7 were considered acceptable. To compare population 
average scores for patients with CDI, the SF-36 was also administered to 82 patients 
given broad-spectrum antibiotics. RESULTS: SF-36 scores were significantly higher 
in healthy controls (72±22) compared to patients on broad-spectrum antibiotics 
(54±12) or patients with CDI (43±17); p< 0.05 each vs. control. The final version of 
the Cdiff36 contained six domains: daily activities (4 items), anxiety (3 items), diet 
(3 items), sleep (2 items), discomfort (6 items), health perception (6 items), dys-
phoria (6 items), relationship (2 items), and social interaction (3 items). CDiff36 
scores correlated significantly based on recurrence vs. primary CDI as well as time 
since last episode (p< 0.05, each). Cdiff36 scales also correlated significantly with the 
SF-36. CONCLUSIONS: The properties of the Cdiff36 should make it appropriate to 
assess changes over time in HRQOL in patients with CDI. Future language transla-
tions and validation will be required for global use of the CDiff36.
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OBJECTIVES: The Food and Drug Administration’s (FDA) clinical trial guidelines for 
development of patient reported outcome (PRO) instruments recommends deriving 
the PRO concepts from the target population using qualitative research. Since the 
PRO instruments currently used in clinical trials of hepatitis C (HCV) patients are 
not developed specifically for this patient population, the FDA’s recommendation 
is not fulfilled. The purpose of this study was to identify a comprehensive list of 
health related quality of life (HRQoL) themes that may be unique to HCV by review-
ing qualitative studies of HCV patients. METHODS: Ovid Medline, Ovid Embase, Ovid 
PsycINFO, and PubMed were searched for peer-reviewed journals from 1946 to 2012. 
Inclusion criteria required primary studies to include HCV patients; be published 
in English; and used qualitative methods to report an aspect of the HCV experi-
ence. Studies were excluded if secondary data was used or there were proxy views. 
Included studies were graded on study quality using the Qualitative Assessment 
and Review Instrument. Eligible studies were then analyzed using meta-synthesis; 
findings from individual studies were grouped into themes which were combined to 
generate HRQoL domains. RESULTS: Ten studies met the inclusion/exclusion crite-
ria and the quality assessment criteria and were included for review. Eleven themes 
were identified: physical symptoms, physical activities, guilt, stigma, emotional 
distress, psychological behavior, social relationship, social activities, work func-
tion, sexual function, and cognitive function. The type of themes identified in each 
study varied by the focus of the primary study and the analytical framework used in 
the qualitative studies. The themes were further grouped into six HRQoL domains: 
physical, psychological/emotional, social, work, sexual, and cognitive functional-
ity. CONCLUSIONS: The systematic review represents a useful starting point in the 
critical appraisal of the PRO instruments used for clinical trials in HCV patients.
Gastrointestinal DisorDers – health care Use & Policy studies
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OBJECTIVES: We assessed the impact on prescription behaviors and drug expendi-
tures of an outpatient prescription incentive program in South Korea that provides 
financial incentives to primary care physicians for less prescription of medi-
cines. METHODS: We focused on drugs for ulcer or gastro-esophageal reflux disease. 
National Health Insurance claims data for years 2009~2012 were extracted from 
1,625 clinics. A clinic-level random effects model was used. RESULTS: The overall 
impact of the program on drug expenditure was not significant. However, clinics in 
general medicine showed a lower prescription rate (-0.8 percentage points), number 
of medicines prescribed (-0.02), prescription duration (-0.15 days), and monthly 
drug expenditure (-740 won) per claim after the policy. Small clinics had lower drug 
expenditure (-650 won) and prescription duration (-0.76 days), while large clinics and 
those in group practice had higher prescription rate (+1.5 and 2.5 percentage points, 
respectively) and number of medicines prescribed (+0.03, group practice only) after 
the policy. CONCLUSIONS: The outpatient prescription incentive program worked 
as intended only in subgroups of minor clinics for the target medicines.
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self-care, or usual activities; 15.8% and 16.5% reported pain/discomfort and anxiety/
depression, respectively. The mean (standard deviation) global health score was 
83.5 (13.3) on a 0 (worst) to 100 (best) scale. Independent predictors of reporting any 
of the EQ-5D health problems included female gender, BMI 25-30 kg/m2, presence 
of comorbidity (hypertension, hyperlipidemia, etc.), family history of liver cancer, 
albumin < 28g/L, and HBeAg positive. Alcohol drinking, a diagnosis of CHB for > 15 
years, and presence of comorbidity were independent predictors of a lower global 
health score, with the effect size ranging between 1 and 4 points. CONCLUSIONS: 
CHB characteristics showed some association with patient-reported health prob-
lems, but their association with general health perception was minimal. The modest 
relationship between clinical and patient-reported outcomes measures supports 
the assessment of patient-reported outcomes in patients with CHB.
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OBJECTIVES: The impact on patient HRQoL of including ribavirin (RBV) in interferon-
free hepatitis C virus (HCV) treatment has not been determined. We assessed the 
HRQoL impact of an all-oral HCV therapy, ombitasvir/paritaprevir/ritonavir and das-
abuvir (OBV/PTV/r+DSV), with and without RBV in treatment naïve, non-cirrhotic, 
GT1a adults at the end of 12-week treatment in Phase 3 PEARL-IV trial. METHODS: 
HCV patients were randomized in a 1:2 ratio to OBV/PTV/r+DSV with RBV or OBV/
PTV/r+DSV without RBV and treated during a 12-week double-blind period. HRQoL 
was assessed using the SF-36v2 Health Survey (SF-36) which was administered 
to patients at baseline, during treatment, at end of treatment (EOT) and at post-
treatment (PT) visits. Physical Component Summary (PCS) and Mental Component 
Summary (MCS) scores were calculated for the SF-36. The statistical significance of 
differences between treatment groups in mean change from baseline to EOT was 
assessed. RESULTS: The analysis included 100 patients on OBV/PTV/r+DSV with 
RBV and 205 on OBV/PTV/r+DSV without RBV. At EOT, mean±SD decrements from 
baseline PCS and MCS scores were observed in the RBV group (change of -0.6±7.19 
in PCS and -2.9±10.55 in MCS) while small increases were observed in the non-RBV 
group (change of +0.9±7.01 in PCS and +0.3±10.09 in MCS). The difference in mean 
change from baseline to EOT did not reach statistical significance for either PCS 
(p-value= 0.105) or MCS (p-value= 0.063). At PT week 24, mean changes from baseline 
were 2.4±5.19 in PCS and 2.6±6.99 in MCS in the RBV group, and 2.2±7.00 in PCS and 
2.0±10.94 in MCS in the non-RBV group. CONCLUSIONS: At the end of 12-week 
treatment in PEARL-IV, the addition of RBV to the interferon-free all-oral OBV/PTV/
r+DSV regimen did not have a significant impact on patient HRQoL in treatment-
naïve GT1a patients. After treatment, PCS and MCS scores for both treatment groups 
showed similar improvement over baseline.
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OBJECTIVES: An all-oral HCV therapy, ombitasvir/paritaprevir/ritonavir and dasa-
buvir (OBV/PTV/r+DSV), without ribavirin (RBV), has been approved by the Food and 
Drug Administration (FDA) for treatment of treatment naïve, non-cirrhotic, GT1b 
adults. We report the HRQoL impact of OBV/PTV/r+DSV, with and without RBV, after 
12-week treatment in the Phase 3 PEARL-III trial. METHODS: HCV patients were ran-
domized in a 1:1 ratio to OBV/PTV/r+DSV with RBV or OBV/PTV/r+DSV without RBV 
and treated during a 12-week double-blind period. HRQoL was assessed using the 
SF-36 v2 Health Survey (SF-36) which was administered to patients at baseline, dur-
ing treatment, at end of treatment (EOT) and at post-treatment (PT) visits. Physical 
Component Summary (PCS) and Mental Component Summary (MCS) scores were 
calculated for the SF-36. The statistical significance of differences between treat-
ment groups in mean change from baseline to EOT was assessed. RESULTS: The 
analysis included 210 patients on OBV/PTV/r+DSV with RBV and 209 on OBV/PTV/
r+DSV without RBV. Among non-cirrhotic subjects with GT1b infection who were 
treated with OBV/PTV/r+DSV without RBV, almost no decrements from baseline 
PCS or MCS scores were observed at EOT (changes [mean±SD] of -0.1±6.71 in PCS 
and -0.1±9.09 in MCS). The decrements OBV/PTV/r+DSV with RBV were numerically 
larger (-0.5±6.80 in PCS and -1.4±9.15 in MCS); however, differences from the non-
RBV group were not statistically significant for either PCS or MCS (p-value= 0.348 
in PCS and p-value= 0.150 in MCS). At PT week 24, mean changes from baseline 
were 1.0±6.20 in PCS and 1.9±8.40 in MCS in the non-RBV group 0.9±6.04 in PCS and 
1.8±7.40 in MCS in the RBV group. CONCLUSIONS: At the end of 12-week treatment 
in PEARL-III, the interferon-free all-oral OBV/PTV/r+DSV regimen in treatment-
naïve GT1b patients had negligible impact on patient HRQoL, regardless of whether 
RBV was co-administered. After treatment, PCS and MCS scores for both treatment 
groups showed similar improvement over baseline.
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